FrancophonIA/ELRC3.0 huggingface dataset:
English: The study showed that Ocaliva was more effective than placebo at reducing the blood levels of bilirubin and ALP: levels decreased by the required amount in 47% (34 out of 73) of patients treated with Ocaliva 10 mg and in 46% (32 out of 70) of patients treated with increasing doses of Ocaliva (from 5 mg up to 10 mg), compared with 10% (7 out of 73) of patients on placebo.
Estonian: Uuringus selgus, et Ocaliva oli vere bilirubiini- ja ALP-sisalduse vähendamisel platseebost efektiivsem: patsiente, kellel need sisaldused vähenesid vajalikus ulatuses, oli 10 mg Ocalivat kasutanute seas 47% (34 patsienti 73st), Ocaliva suurenevaid annuseid (5 mg kuni 10 mg) kasutanute seas 46% (32 patsienti 70st) ja platseeborühmas 10% (7 patsienti 73st).
English: This may lead to scarring and liver failure, and may increase the risk of liver cancer.
Estonian: See võib põhjustada maksa sidekoestumist ja maksapuudulikkust ning suurendada maksavähi tõenäosust.
English: The measure of effectiveness was based on the number of patients whose blood levels of the substances bilirubin and ALP (markers of liver damage) decreased by at least 15% (for ALP) and below a certain value considered normal (for bilirubin) after 1 year of treatment.
Estonian: Efektiivsuse näitaja põhines nende patsientide arvul, kellel vähenesid vere bilirubiini- ja ALP-sisaldus (maksakahjustuse markerid) vähemalt 15% võrra (ALP) ja alla teatud normaalväärtuse (bilirubiin) pärast 1-aastast ravi.
English: What are the risks associated with Ocaliva?
Estonian: Mis riskid Ocalivaga kaasnevad?
English: Ocaliva must not be used in patients whose bile ducts are completely blocked.
Estonian: Ocalivat ei tohi kasutada patsiendid, kelle sapijuhad on täielikult ummistunud.
English: For more information about using Ocaliva, see the package leaflet or contact your doctor or pharmacist.
Estonian: Kui vajate Ocalivaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: It is used together with another medicine, ursodeoxycholic acid (UDCA), in patients who do not respond sufficiently to UDCA alone, and on its own in patients who cannot take UDCA.
Estonian: Seda kasutatakse koos teise ravimi ursodeoksühoolhappega (UDCA) patsientidel, kellel ei teki ainult UDCA-ga piisavat ravivastust, ja ainuravimina patsientidel, kes ei saa UDCA-d võtta.
English: Itching is also the most common side effect that can lead to discontinuation of treatment.
Estonian: Sügelus on ka kõrvalnäht, mille tõttu kõige sagedamini ravi katkestatakse.
English: Side effects reported with Ocaliva are carefully evaluated and any necessary action taken to protect patients.
Estonian: Ocaliva kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Reductions in bilirubin and ALP were to an extent which is indicative of an improvement in the condition of the liver.
Estonian: Bilirubiini- ja ALP-sisaldus vähenes määral, mis osutab maksa seisundi paranemisele.
English: Ocaliva was compared with placebo (a dummy treatment) in a main study involving 217 adults with primary biliary cholangitis who either had been taking UDCA for at least 1 year, or who could not take UDCA.
Estonian: Ovalivat võrreldi platseeboga (näiv ravim) põhiuuringus, milles osales 217 primaarse biliaarse kolangiidiga täoiskasvanut, kes olid võtnud UDCA-t vähemalt 1 aasta või kes ei saanud UDCA-d võtta.
English: The first study is designed to demonstrate the clinical benefit of Ocaliva, while the second study will investigate the benefits of Ocaliva in patients with moderate to severe liver disease.
Estonian: Esimeses uuringus kavatsetakse tõendada Ocaliva kliinilist kasulikkust ja teises uuritakse Ocaliva kasulikkust keskmise kuni raske maksahaigusega patsientidel.
English: Ocaliva has been shown to reduce the blood levels of bilirubin and ALP in patients with primary biliary cholangitis, including those who could not be treated with UDCA.
Estonian: On tõendatud, et Ocaliva vähendab vere bilirubiini- ja ALP-sisaldust primaarse biliaarse kolangiidiga patsientidel, sealhulgas neil, kes ei saa kasutada UDCA-ravi.
English: Primary biliary cholangitis is an autoimmune condition in which there is gradual destruction of the small bile ducts in the liver.
Estonian: Primaarne biliaarne kolangiit (primaarne sapijuhapõletik) on autoimmuunne seisund, mille korral järkjärgult hävinevad maksas olevad väikesed sapijuhad.
English: The most common side effects with Ocaliva are itching (which may affect more than 6 in 10 people) and tiredness (which may affect more than 2 in 10 people).
Estonian: Ocaliva kõige sagedamad kõrvalnähud on sügelus (võib esineda enam kui 6 patsiendil 10st) ja väsimus (võib esineda enam kui 2 patsiendil 10st).
English: In the majority of cases seen, itching occurred within the first month of treatment and tended to resolve over time while continuing treatment.
Estonian: Enamasti esines sügelus esimese ravikuu jooksul ja tavaliselt leevenes ravi jätkudes.
English: What information is still awaited for Ocaliva?
Estonian: Mis teavet Ocaliva kohta veel oodatakse?
English: Ocaliva has been given ‘conditional authorisation'.
Estonian: Ocaliva on saanud müügiloa tingimusliku heakskiidu alusel.
English: Ocaliva is available as tablets (5 and 10 mg) and can only be obtained with a prescription.
Estonian: Ocalivat turustatakse tablettidena (5 ja 10 mg).
English: Other information about Ocaliva
Estonian: Muu teave Ocaliva kohta
English: Primary biliary cholangitis is rare, and Ocaliva was designated an ‘orphan medicine' (a medicine used in rare diseases) on 27 July 2010.
Estonian: Primaarne biliaarne kolangiit esineb harva ja Ocaliva nimetati 27. juulil 2010 harvikravimiks.
English: Ocaliva contains the active substance obeticholic acid.
Estonian: Ocaliva sisaldab toimeainena obetikoolhapet.
English: The active substance in Ocaliva, obeticholic acid, is a modified form of a bile acid (the main components of bile).
Estonian: Ocaliva toimeaine obetikoolhape on sapphappe (sapi põhikomponendi) muudetud vorm.
English: Patients with primary biliary cholangitis have limited treatment options.
Estonian: Primaarse biliaarse kolangiidiga patsientide ravivõimalused on piiratud.
English: How is Ocaliva used?
Estonian: Kuidas Ocalivat kasutatakse?
English: After a few months, if Ocaliva is well tolerated the dose can be increased.
Estonian: Kui patsient talub Ocalivat hästi, tohib mõne kuu pärast annust suurendada.
English: How does Ocaliva work?
Estonian: Kuidas Ocaliva toimib?
English: By attaching to these receptors, Ocaliva reduces the production of bile in the liver, preventing it from building up and damaging the liver tissue.
Estonian: Nende retseptoriga seondudes vähendab Ocaliva sapi teket maksas, takistades selle kogunemist ja maksakoe kahjustamist.
English: However, the clinical benefits of Ocaliva need to be demonstrated in further studies.
Estonian: Samas on vaja veel uuringuid, mis tõendavad Ocaliva kliinilist kasulikkust.
English: What benefits of Ocaliva have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Ocaliva kasulikkus?
English: Ocaliva is used to treat adults with a liver disease known as primary biliary cholangitis.
Estonian: Ocalivat kasutatakse teatud maksahaiguse, primaarse biliaarse kolangiidiga täiskasvanute raviks.
English: An overview of Ocaliva and why it is authorised in the EU
Estonian: Ülevaade ravimist Ocaliva ja ELis müügiloa väljastamise põhjendus
English: It works mainly by attaching to receptors in the liver and gut (farnesoid X receptors) which control the production of bile.
Estonian: Selle peamine toimemehhanism on seondumine maksa ja soole teatud retseptoritega (FXR-retseptoritega), mis reguleerivad sapi teket.
English: Doses can be reduced or treatment may need to be stopped in patients who experience intolerable itching (a possible side effect with Ocaliva).
Estonian: Kui patsiendil tekib talumatu sügelus (Ocaliva võimalik kõrvalnäht), tuleb annust vähendada või ravi lõpetada.
English: These ducts transport fluid called bile from the liver to the intestines, where it is used to help digest fats.
Estonian: Nendes liigub sapp maksast soolde, kus osaleb rasvade seedimises.
English: For the list of all side effects with Ocaliva, see the package leaflet.
Estonian: Ocaliva kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Why is Ocaliva authorised in the EU?
Estonian: ELis Ocalivale väljastatud müügiloa põhjendus
English: As a result of the damage to the ducts, bile builds up in the liver causing damage to the liver tissue.
Estonian: Kui sapijuhad on kahjustunud, koguneb sapp maksa ja kahjustab maksakude.
English: Intravenous use vial (glass)
Estonian: Intravenoosne viaal (klaasist)
English: Tarceva is taken at least one hour before or two hours after food.
Estonian: Tarcevat võetakse vähemalt 1 tund enne või 2 tundi pärast sööki.
English: Tarceva (erlotinib)
Estonian: Tarceva (erlotiniib)
English: Tarceva received a marketing authorisation valid throughout the EU on 19 September 2005.
Estonian: Tarceva on saanud müügiloa, mis kehtib kogu Euroopa Liidus, 19. septembril 2005.
English: Pancreatic cancer
Estonian: Kõhunäärmevähk
English: What measures are being taken to ensure the safe and effective use of Tarceva?
Estonian: Mis meetmed võetakse, et tagada Tarceva ohutu ja efektiivne kasutamine?
English: Further information on Tarceva can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Tarceva.
Estonian: Lisateave Tarceva kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/Tarceva.
English: The medicine is available as tablets (25, 100 and 150 mg).
Estonian: Ravimit turustatakse tablettidena (25, 100 ja 150 mg).
English: It is used for:
Estonian: Seda kasutatakse järgmistel patsientidel:
English: Patients taking Tarceva should stop smoking, as smoking can decrease the amount of the medicine in the blood.
Estonian: Tarcevat võtvad patsiendid peavad loobuma suitsetamisest, sest see võib vähendada ravimi sisaldust veres.
English: Other information about Tarceva
Estonian: Muu teave Tarceva kohta
English: What is Tarceva and what is it used for?
Estonian: Mis on Tarceva ja milleks seda kasutatakse?
English: As for all medicines, data on the use of Tarceva are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Tarceva kasutamise kohta pidevat järelevalvet.
English: As a result of this block, the tumour cells can no longer receive the messages needed for growing and for spreading (metastasis).
Estonian: Selle tulemusena ei saa kasvajarakud enam vastu võtta kasvuks ja levikuks (metastaseerumiseks) vajalikke signaale.
English: Stable means that the cancer has neither improved nor worsened with chemotherapy (medicines to treat cancer);
Estonian: Stabiilne tähendab, et vähk ei ole keemiaraviga (vähiravimid) paranenud ega süvenenud;
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tarceva have been included in the summary of product characteristics and the package leaflet.
Estonian: Tarceva ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: As Tarceva seems more effective in patients with pancreatic cancer who develop a rash, treatment should be re-assessed after 4 to 8 weeks if no rash has developed.
Estonian: Et Tarceva näib olevat efektiivsem kõhunäärmevähiga patsientidel, kellel tekib lööve, tuleb ravi 4-8 nädala pärast uuesti hinnata, kui löövet ei ole tekkinud.
English: As a result, Tarceva helps to stop the cancer from growing and spreading through the body.
Estonian: Seega aitab Tarceva peatada vähirakkude kasvu ja levikut organismis.
English: The European Medicines Agency therefore decided that Tarceva's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Euroopa Ravimiamet otsustas, et Tarceva kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: For more information about using Tarceva, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Tarceva kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Side effects reported with Tarceva are carefully evaluated and any necessary action taken to protect patients.
Estonian: Tarceva kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: The study found no advantage to early use of the medicine, as patients treated with Tarceva early in the study did not live longer than those treated with Tarceva later in the study (after the disease had progressed).
Estonian: Uuring ei tõendanud ravimi varajase kasutamise eelist, sest Tarcevat uuringu varases etapis kasutanud patsiendid ei elanud kauem kui patsiendid, kes kasutasid Tarcevat uuringu hilisemas etapis (pärast haiguse progresseerumist).
English: Tarceva can only be obtained with a prescription and treatment should be supervised by a doctor who has experience in the use of cancer medicines.
Estonian: Tarceva on retseptiravim ja ravi peab jälgima vähiravimite kasutamises kogenud arst.
English: The active substance in Tarceva, erlotinib, belongs to the group ‘EGFR inhibitors'.
Estonian: Tarceva toimeaine erlotiniib kuulub EGFRi inhibiitorite rühma.
English: If needed (for example because of side effects), the dose may be reduced in 50-mg steps.
Estonian: Annust võib vajaduse korral (näiteks kõrvalnähtude tõttu) 50 mg kaupa vähendada.
English: The medicine contains the active substance erlotinib.
Estonian: Ravim sisaldab toimeainena erlotiniibi.
English: For pancreatic cancer, it is 100 mg daily.
Estonian: Kõhunäärmevähi korral on tavaannus 100 mg ööpäevas.
English: • patients with EGFR activating mutations whose disease is stable after initial chemotherapy.
Estonian: • EGFRi aktiveerivate mutatsioonidega patsiendid, kellel haigus on esialgse keemiaravi järel stabiilne.
English: What benefits of Tarceva have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Tarceva kasulikkus?
English: Tarceva can prolong the time the patients live without their disease getting worse and prolong life in some patients.
Estonian: Tarceva võib pikendada haiguse süvenemiseni kuluvat aega ja ka teatud patsientide elumust.
English: For the full list of side effects and restrictions with Tarceva, see the package leaflet.
Estonian: Tarceva kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Tarceva is a cancer medicine used in non-small-cell lung cancer (NSCLC) that is advanced (the cancer has started to spread) or metastatic (it has already spread to other parts of the body).
Estonian: Tarceva on vähiravim, mida kasutatakse kaugelearenenud (vähk on hakanud organismis levima) või metastaatilise (vähk on juba levinud organismis ka mujale) mitteväikerakk-kopsuvähi korral.
English: • The fourth study compared Tarceva with placebo in 731 patients in whom at least one previous chemotherapy treatment had not worked.
Estonian: • Neljandas uuringus võrreldi Tarcevat platseeboga 731 patsiendil, kellel ei toiminud vähemalt üks varasem keemiaravikuur.
English: Tarceva is also used in patients with metastatic pancreatic cancer, in combination with gemcitabine (another cancer medicine).
Estonian: Tarcevat kasutatakse ka metastaatilise kõhunäärmevähiga patsientidel koos gemtsitabiiniga (samuti vähiravim).
English: In the study of Tarceva used in combination with gemcitabine for pancreatic cancer, the most common side effects were tiredness (affecting 73% of patients), rash (69%) and diarrhoea (48%).
Estonian: Uuringus, milles Tarcevat kasutati kõhunäärmevähiga patsientidel koos gemtsitabiiniga, olid kõige sagedamad kõrvalnähud väsimus (73% patsientidest), lööve (69% patsientidest) ja kõhulahtisus (48% patsientidest).
English: The study compared how long patients survived when Tarceva was used early in the study with how long they survived when Tarceva was used later in the study.
Estonian: Uuringus võrreldi patsientide elumust Tarceva kasutamisel uuringu varases etapis ja selle kasutamisel hilisemas etapis.
English: For NSCLC, the usual dose is 150 mg daily.
Estonian: Mitteväikerakk-kopsuvähi korral on tavaannus 150 mg ööpäevas.
English: The greatest benefit was in a subgroup of 49 patients with EGFR activating mutations: those taking Tarceva (22 patients) lived for an average of 44.6 weeks without their disease getting worse, compared with 13 weeks for those taking placebo (27 patients).
Estonian: Suurimat kasulikkust täheldati 49 EGFRi aktiveerivate mutatsioonidega patsiendist koosnenud allrühmas, kus keskmine progresseerumiseta elumus oli Tarcevat kasutanud patsientidel (22 patsienti) 44,6 nädalat ja platseebot kasutanud patsientidel (27 patsienti) 13 nädalat.
English: How is Tarceva used?
Estonian: Kuidas Tarcevat kasutatakse?
English: However, there was no advantage for patients whose cancer had not spread beyond the pancreas.
Estonian: Patsientidel, kelle vähk ei olnud levinud kõhunäärmest mujale, Tarceva soodsat mõju siiski ei avaldanud.
English: Patients taking Tarceva survived for an average of 6.7 months, compared with 4.7 months for the patients taking placebo.
Estonian: Tarcevat kasutanud patsientide keskmine elumus oli 6,7 kuud ja platseebot kasutanud patsientidel 4,7 kuud.
English: The side effects reported with Tarceva are considered manageable.
Estonian: Ravimi kõrvalnähte peetakse hallatavaks.
English: • A third study compared Tarceva with placebo in 643 patients with advanced NSCLC whose cancer cells did not have EGFR activating mutations and whose disease was stable after 4 cycles of treatment with platinum-containing chemotherapy.
Estonian: • Kolmandas uuringus võrreldi Tarcevat platseeboga 643 kaugelearenenud mitteväikerakkkopsuvähiga patsiendil, kellel ei olnud vähirakkudes EGFRi aktiveerivaid mutatsioone ja kelle haigus oli pärast ravi plaatinapõhise keemiaraviga (4 tsüklit) stabiilne.
English: In studies, the most common side effects with Tarceva when used as monotherapy for lung cancer were rash (affecting 75% of patients), diarrhoea (54%), loss of appetite and tiredness (52% each).
Estonian: Uuringutes olid kopsuvähiga patsientidel monoteraapiana kasutatud Tarceva kõige sagedamad kõrvalnähud lööve (75% patsientidest), kõhulahtisus (54% patsientidest), isutus ja väsimus (kumbki 52% patsientidest).
English: • The second study compared Tarceva with placebo (a dummy treatment) in 889 patients with advanced or metastatic NSCLC whose disease had not got worse after 4 cycles of treatment with platinum-containing chemotherapy.
Estonian: • Teises uuringus võrreldi Tarcevat platseeboga (näiv ravim) 889 kaugelearenenud või metastaatilise mitteväikerakk-kopsuvähiga patsiendil, kelle haigus ei olnud süvenenud pärast ravi plaatinapõhise keemiaraviga (4 tsüklit).
English: An overview of Tarceva and why it is authorised in the EU
Estonian: Ülevaade ravimist Tarceva ja ELis müügiloa väljastamise põhjendus
English: Patients with NSCLC should be tested for EGFR activating mutation before starting Tarceva, unless previous chemotherapy has not worked and other treatments are not suitable.
Estonian: Enne ravi alustamist Tarcevaga tuleb mitteväikerakk-kopsuvähiga patsientidel testida EGFRi aktiveerivate mutatsioonide esinemist, v.a juhul, kui varasem keemiaravi ei toiminud ja muud ravimeetodid ei sobi.
English: • patients with EGFR activating mutations in whom previous chemotherapy has not worked;
Estonian: • EGFRi aktiveerivate mutatsioonidega patsiendid, kellel varasem keemiaravi ei toiminud;
English: In NSCLC, Tarceva has been mainly studied in four studies.
Estonian: Seoses mitteväikerakk-kopsuvähiga uuriti Tarcevat peamiselt 4 uuringus.
English: Among the patients who took Tarceva, the average survival was 8.6 months in those whose tumours were ‘EGFR IHC-positive' (had EGFRs on the cell surface), and 5.0 months in those whose tumours were EGFR IHC-negative.
Estonian: Tarcevat kasutanud patsientidest oli immunohistokeemiauuringul tuvastatud EGFR-positiivse kasvajaga (kasvajarakkude pinnal oli epidermaalse kasvufaktori retseptoreid) patsientide keskmine elumus 8,6 kuud ja EGFR-negatiivse kasvajaga patsientidel 5,0 kuud.
English: • patients without EGFR activating mutations in whom previous chemotherapy has not worked and other treatments are unsuitable.
Estonian: • EGFRi aktiveerivate mutatsioonideta patsiendid, kellel varasem keemiaravi ei toiminud ning kellele ei sobi muud ravimeetodid.
English: What are the risks associated with Tarceva?
Estonian: Mis riskid Tarcevaga kaasnevad?
English: • previously untreated patients whose cancer cells have certain changes (‘activating mutations') in the gene for a protein called epidermal growth factor receptor (EGFR);
Estonian: • varem ravimata patsiendid, kelle vähirakkudes on teatud muutused (aktiveerivad mutatsioonid)
English: • The first study compared Tarceva with chemotherapy in 173 patients with advanced NSCLC with activating EGFR mutations who had not received previous chemotherapy.
Estonian: • Esimeses uuringus võrreldi Tarcevat keemiaraviga 173 kaugelearenenud ja EGFRi aktiveerivate mutatsioonidega mitteväikerakk-kopsuvähiga patsiendil, kes ei olnud varem saanud keemiaravi.
English: Patients with metastatic cancer taking Tarceva as initial therapy lived without their disease getting worse for an average of 5.9 months, compared with 5.1 months in those taking placebo.
Estonian: Tarcevat esmaravina kasutanud metastaatilise vähiga patsientide keskmine progresseerumiseta elumus oli 5,9 kuud ja platseebot kasutanud patsientidel 5,1 kuud.
English: Overall, Tarceva marginally increased how long patients lived without their disease getting worse and how long they survived.
Estonian: Üldiselt pikendas Tarceva haiguse süvenemiseni kulunud aega ja elumust vähesel määral.
English: Tarceva in combination with gemcitabine was studied in 569 patients with pancreatic cancer that was advanced, unresectable (that cannot be removed by surgery) or metastatic.
Estonian: Kõhunäärmevähi ravis uuriti Tarceva kasutamist koos gemtsitabiiniga 569 patsiendil, kellel oli kaugelearenenud, opereerimatu või metastaatiline kõhunäärmevähk.
English: How does Tarceva work?
Estonian: Kuidas Tarceva toimib?
English: Patients taking Tarceva lived for an average of 10.4 months without their disease getting worse compared with 5.1 months for those receiving chemotherapy medicines.
Estonian: Tarcevaga ravitud patsientide keskmine progresseerumiseta elumus oli 10,4 kuud ja keemiaraviga ravitud patsientidel 5,1 kuud.
English: Erlotinib blocks EGFRs, which can be found on some tumour cells.
Estonian: Erlotiniib blokeerib teatud kasvajarakkude pinnal olevad epidermaalse kasvufaktori retseptorid (EGFR).
English: Why is Tarceva authorised in the EU?
Estonian: ELis Tarcevale väljastatud müügiloa põhjendus
English: Italy, Portugal: Inibace Plus
Estonian: Itaalia, Portugal: Inibace Plus
English: - Low blood pressure.
Estonian: - madal vererõhk.
English: The usual dose is one tablet each day.
Estonian: Tavaannuseks on üks tablett päevas.
English: They are used together when treatment with just one is insufficient.
Estonian: Neid kasutatakse koos juhul, kui nende kasutamine eraldi oli ebapiisav.
English: Clinical/Efficacy Studies
Estonian: Kliinilised uuringud/tõhususuuringud
English: - if you are planning to have an operation (including dental surgery).
Estonian: (desensitisatsioon); - kui teil on plaanis minna operatsioonile (sealhulgas hambaoperatsioonile).
English: Austria: Inhibace Plus “Roche” Belgium, Luxembourg: Co-Inhibace Cyprus, Greece: Vascace Plus Czech Republic, Hungary, Poland, Spain: Inhibace Plus Germany: Dynorm Plus
Estonian: Austria: Inhibace Plus “Roche” Belgia, Luksemburg: Co-Inhibace Küpros, Kreeka: Vascace Plus Tšehhi Vabariik, Ungari, Poola, Hispaania: Inhibace Plus Saksamaa: Dynorm Plus
English: Severe reactions:
Estonian: Tõsised reaktsioonid
English: This phenomenon appeared to be more likely to occur during the first weeks of combined treatment and in patients with renal impairment.
Estonian: Ilmnes, et see fenomen tekib suurema tõenäosusega kombineeritud ravi esimestel nädalatel ja neerukahjustusega patsientidel.